FLT3-activating mutations (typically ITD in 25% of AML cases and tyrosine kinase domain (TKD) point mutations in ~5%) result in constitutively activated FLT3 signaling independent of ligand binding, representing one of the most prevalent driver mutations in AML with an overall incidence of ~30%. This evidence concerns the gene FLT3 and acute myeloid leukemia.